Reductions in Absolute PASI Over 144 Weeks of Treatment with Certolizumab Pegol in Patients with Plaque Psoriasis: Pooled Analysis from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)

A.B. Gottlieb, A. Blauvelt, D. Thaci, Y. Poulin, F. Brock, C. Arendt, M. Boehnlein, K. Reich

Presented at Fall Clinical Dermatology Conference 2020 | October 29–November 1 | Las Vegas, NV

Synopsis
Patients with moderate to severe plaque psoriasis were treated with certolizumab pegol for up to 144 weeks, initially dosed at either 200 mg or 400 mg every two weeks. High proportions of patients achieved and maintained stringent absolute PASI thresholds.

Objectives
To assess the long-term maintenance of absolute PASI <5, <3, and <1 in patients with moderate to severe plaque psoriasis treated with certolizumab pegol for up to 144 weeks, including patients who entered a 144-week open-label extension (OLE).

Background
- Plaque psoriasis (PsO) is an immune-mediated, inflammatory disease that affects around 2–4% of adults.1
- Certolizumab pegol (CZP) is an IgG4, Fc-fusion anti-tumor necrosis factor anti-TNF with demonstrated efficacy and safety in the treatment of moderate to severe PsO.2
- An absolute Psoriasis Area and Severity Index (PSI) score ≤5 has been associated with good quality of life in patients with PsO, while a PSI score ≤3 is considered excellent.3

Methods
Study Design
- Data were pooled from two phase 3 trials in adults with PsO: CIMPASI-1 (NCT02326298) and CIMPASI-2 (NCT02326272).
- At Week 0, patients were randomized 2:2:1 to receive CZP 200 mg Q2W, CZP 400 mg Q2W, or placebo.
- Patients included in this analysis were either:
  - Randomized to CZP 200 mg Q2W or CZP 400 mg Q2W at Week 0, or;
  - Patients who entered an open-label CZP 200 mg Q2W to 400 mg Q2W dose transition period at Week 16 and entered the open-label CZP 400 mg Q2W escape arm.

Results
- In CZP 200 mg Q2W-randomized patients (n=186), responder rates decreased during the OLE following mandatory dose adjustments at Week 16.
- In CZP 400 mg Q2W-randomized patients (n=175), responder rates were sustained to Week 144.

Conclusions
- High proportions of patients dosed with both CZP 400 mg Q2W and CZP 200 mg Q2W achieved and maintained stringent absolute PASI thresholds.